Aug 14, 2018
This episode summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them.
Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making.
Next-generation sequencing (NGS) has moved from the realm of research into those of clinical development, drug approval and clinical diagnostics, as the cost has decreased and the reliability of the underlying technologies has increased. However, the process of translating raw reads into reliable genotypes is still subject to much variability. This variability presents a challenge when using NGS in the regulated domain of the drug development process.
This article was written by Keith Nangle & Mike Furness
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: